SCHEMBL31371742
Dual Butyrylcholinesterase and p38 Mitogen-Activated Protein Kinase Inhibitor. IC50 hBChE 0.772 +/- 0.057 microM; IC50 p38alpha MAPK 0.191 +/- 0.021 microM; residual activity at 100 microM AChE 53 +/- 1 %
General
Type : Multitarget, Carboxamide, Indazole, p38-MAPK-inhibitor
Chemical_Nomenclature : 1-(cyclohexylmethyl)-5-[(2,4-difluorophenyl)methyl]-N-[2-(dimethylamino)ethyl]indazole-6-carboxamide
Canonical SMILES : CN(C)CCNC(=O)C1=C(C=C2C=NN(C2=C1)CC3CCCCC3)CC4=C(C=C(C=C4)F)F
InChI : InChI=1S\/C26H32F2N4O\/c1-31(2)11-10-29-26(33)23-15-25-21(16-30-32(25)17-18-6-4-3-5-7-18)13-20(23)12-19-8-9-22(27)14-24(19)28\/h8-9,13-16,18H,3-7,10-12,17H2,1-2H3,(H,29,33)
InChIKey : KRBANHWMWFMMPJ-UHFFFAOYSA-N
Other name(s) : 1-(Cyclohexylmethyl)-5-(2,4-difluorobenzyl)-N-(2-(dimethylamino)ethyl)-1H-indazole-6-carboxamide || Compound 95 || A1A2L
MW : 454.6
Formula : C26H32F2N4O
CAS_number :
PubChem : 176205238
UniChem : KRBANHWMWFMMPJ-UHFFFAOYSA-N
Target
References (1)
| Title : Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38alpha Mitogen-Activated Protein Kinase Inhibitors - Ferjancic Benetik_2025_J.Med.Chem__ |
| Author(s) : Ferjancic Benetik S , Proj M , Knez D , Kosak U , Meden A , Krajsek K , Pislar A , Horvat S , Svajger U , Tesic N , Pulkrabkova L , Soukup O , Skarka A , Andrys R , Brazzolotto X , Igert A , Nachon F , Dias J , Detka J , Gdula-Argasinska J , Wyska E , Szafarz M , Manik A , Plachtij N , Musilek K , Salat K , Obreza A , Gobec S |
| Ref : Journal of Medicinal Chemistry , : , 2025 |
| Abstract : |
| PubMedSearch : Ferjancic Benetik_2025_J.Med.Chem__ |
| PubMedID: 40779804 |